Glenmark Pharmaceuticals Limited has informed the Exchange regarding a press release dated October 23, 2025, titled "Glenmark Pharmaceuticals Inc., USA to launch Ropivacaine Hydrochloride Injection USP, 40 mg/20 mL (2mg/mL), 150 mg/30 mL (5 mg/mL), and 200 mg/20 mL (10 mg/mL) Single-Dose Vials".
GLENMARK · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Glenmark Pharmaceuticals Inc., USA is launching Ropivacaine Hydrochloride Injection in three single-dose vial formats: 40 mg/20 mL (2 mg/mL), 150 mg/30 mL (5 mg/mL), and 200 mg/20 mL (10 mg/mL). Ropivacaine is a local anesthetic used in surgery and pain management. The US launch indicates the product has cleared the required regulatory approvals for the American market. This adds to Glenmark's injectable portfolio in the US, which remains its largest and most important market. The Ropivacaine segment in the US is competitive but represents a steady demand from hospitals and surgical centres.
Marginally positive for shareholders as the product line extension in the US supports top-line growth, though the actual revenue contribution will depend on how quickly Glenmark captures market share against established players in the injectable anesthetics space.